In April, ministers recalled Parliament on a Saturday to pass emergency legislation and stop the last blast furnace in Britain from going cold. It was a dramatic moment, treated at the time as a one-off act of industrial rescue. Four months on, the accounts have arrived, and they tell a less dramatic but more revealing story. British Steel owed close to £1bn to companies connected to its former owner Jingye when the state took over, money that an independent valuer will now have to untangle before anyone can say what, if anything, is owed back. Reform's Richard Tice wants the government to refuse repayment outright, arguing taxpayers should not reward a Chinese owner for running the business into the ground. The government's own justification for stepping in cited the impact on the economy, on critical national infrastructure and on national security. That phrase, critical national infrastructure, is doing more work than it might first appear, and it points somewhere the government has been slower to look.

The lesson of British Steel is not really about steel. It is about what happens when a country designates something critical only after the private owner behind it has already failed, leaving the state to intervene at speed, absorb the debt, and negotiate compensation from a position of weakness rather than foresight. That pattern should be uncomfortably familiar to anyone watching how the NHS sources its medicines. A House of Lords committee reported in February that most active pharmaceutical ingredients used in NHS medicines are controlled by China, India or a small number of other single-source suppliers, that roughly four in five prescribed medicines are generics, and that only about a quarter of those are manufactured in the UK. The same report found that government and the NHS routinely react to supply disruption after it has already reached patients, with thin oversight from the Department of Health and Social Care and little coordinated leadership over where the exposure actually sits. It called medicine supply what British Steel has now forced ministers to treat steel as: a national security question, not a procurement footnote.

The parallel extends beyond medicines. The Federated Data Platform, built with Palantir, and the electronic patient record systems that run much of the NHS estate, including Epic's, sit with a small number of vendors whose contractual terms make departure costly and, in places, clinically risky. None of this is foreign ownership failure in the way Jingye's was. But it shares the underlying structural flaw that British Steel has just made expensive and visible: dependency that goes unpriced until the moment it is tested, at which point the state has no leverage left to negotiate from strength. Ministers did not choose to nationalise British Steel from a position of confidence. They did it because the alternative was losing sovereign steelmaking capacity altogether, and the debt now being disputed is the price of having let that dependency run unmanaged for years.

None of this means the NHS faces an imminent Scunthorpe moment over medicines or data platforms. The scale and mechanics are different, and a supply shortage is not the same as an ownership collapse. But the government's own language around British Steel, critical infrastructure, national security, sovereign capability, is precisely the vocabulary the Lords committee has already applied to medicine supply, without yet triggering the kind of proactive intervention steel eventually received. The £555m already committed to British Steel, and the near-£1bn dispute now sitting with an independent valuer, is what reactive nationalisation costs when a government waits for a crisis to define what counts as critical. Health ministers have the advantage steel did not: a report on their desk naming the risk before the failure, not after it. Whether that advantage gets used, or filed alongside the last one, is the more interesting question than anything Jingye's accountants will settle this year.